Medtronic's AdaptivCRT Trial Show 50% Atrial Fibrillation Risk Reduction

(RTTNews) - Medtronic, Inc.(MDT), Monday said its AdaptivCRT technology reduced 50 percent atrial fibrillation or AF risk in heart failure patients. The results were presented today at a clinical trial at the Heart Failure Society of America's meeting, the company said. The AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators or CRT-Ds that continually adjusts therapy to a patient's natural heart rhythms and minimizes the amount of unnecessary right ventricular or RV pacing.

The Adaptive CRT trial is designed to weigh the clinical benefit of synchronized left ventricular pacing or sLVP provided by the AdaptivCRT algorithm. The technology uses the heart's natural rhythm to continuously adjust therapy, resulting the patients in the study who received AdaptivCRT to experience a 34 percent reduction in right ventricular pacing compared to conventional CRT. Long-term study outcomes presented show that patients receiving the AdaptivCRT technology were at a 46 percent lower risk of spending 48 consecutive hours or more in AF compared to conventional CRT patients.

Earlier research showed that the use of the AdaptivCRT feature saw a 21 percent reduction in overall heart failure hospitalizations within the first year after implant, as compared to historical CRT trials. The company added that these results also reinforced the safety and effectiveness of the AdaptivCRT feature.

The AdaptivCRT have been available in the United States since May 2013 and in Europe since 2012.